bortezomib
information and resources from the National Cancer Institute
NCI Thesaurus | bortezomib
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.NCI Thesaurus | bortezomib
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.
|
|
|
|
news articles
CuraGen and TopoTarget Announce Initiation of First NCI-sponsored ... Mar 29, 2006
Yahoo! News (press release) ...trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with bortezomib (Velcade®) for ...
CuraGen, TopoTarget Initiate Patient Dosing In Phase I Clinical ... Mar 29, 2006
Trading Markets, ...and lymphomas. The company noted that the inhibitor was tried in combination with bortezomib. This ... for bortezomib. Curagen noted that ...
CuraGen and TopoTarget Announce Initiation of First NCI-sponsored ... Mar 29, 2006
PR Newswire (press release), ...- Phase I trial to evaluate PXD101 plus bortezomib (Velcade(R)) for the treatment of advanced solid tumors and lymphoma - BRANFORD, Conn ... for bortezomib. ...
TopoTarget and CuraGen announce initiation of first NCI-sponsored ... Mar 29, 2006
PharmaLive.com (press release), ...be sponsored by the US National Cancer Institute (NCI) and will evaluate the safety and tolerability of PXD101 in combination with bortezomib (Velcade®) for ...
CuraGen and TopoTarget begin trial of anticancer compound Mar 30, 2006
Pharmaceutical Business Review ..."Based on the reported preclinical findings for PXD101 and bortezomib (Velcade), these compounds appear to work through distinct pathways that are ...
Cytogen Announces Schedule for Clinical Data Presentations at ... Mar 23, 2006
PR Newswire (press release), ...especially pleased that interim data will be presented from one of the first combination trials of QUADRAMET with the protease inhibitor bortezomib (Velcade(R ...
Scientists Making Advances In Cancer To Receive International ... Mar 25, 2006
Medical News Today (press release), He is being honored for the synthesis of the first selective proteasome inhibitor, bortezomib (VELCADE), for recognizing the potential of a proteasome ...
CuraGen and TopoTarget begin cancer study Mar 24, 2006
Pharmaceutical Business Review ...phase Ib/II proof-of-concept trial will examine PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade (bortezomib) for the ...
CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with ... Mar 22, 2006
PR Newswire (press release), Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade(R) (bortezomib) for the ...
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center ... Mar 2, 2006
PharmaLive.com (press release), ...first half of 2006, including another corporate-sponsored DFCI -led phase I/II study evaluating the safety and efficacy of KRX-0401 and bortezomib (Velcade(R ...
Millennium Achieves $10 Million Milestone Payment Mar 9, 2006
PharmaLive.com (press release), ...payment from Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) based on sales milestones reached for VELCADE(R) (bortezomib) for Injection ...
Millennium and Johnson & Johnson Pharmaceutical Research & ... Mar 6, 2006
PR Newswire (press release), ...one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should ...
Kosan Reports 2005 Fourth Quarter and Year End Results Mar 2, 2006
Yahoo! News (press release) 2005 Product Development Highlights Hsp90 Inhibitor Program -- Demonstration of clinical activity of KOS-953 in combination with bortezomib (Velcade®) in ...
Millennium Pharmaceuticals: more Velcade ventures Mar 7, 2006
Pharmaceutical Business Review Velcade's uptake. The trial will study the effects of Velcade (bortezomib) in patients with NSCLC who have failed prior chemotherapy. It ...
(PRN) - 485 Courts in Session With Tyler's INCODE Municipal Court ... Mar 6, 2006
Bolsamania.com, ...(PRN) - Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in ...
Bio-IT Briefs Mar 9, 2006
Bio-IT World, ...payment from Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) based on sales milestones reached for Velcade (bortezomib) for Injection in ...
Updated Results with Velcade® in Multiple Myeloma Mar 3, 2006
Cancer Consultants (press release), According to results recently published in the journal Cancer, updated results from a clinical trial evaluating Velcade® (bortezomib) in the treatment of ...
Lehman Brothers Ninth Annual Global Healthcare Conference to ... Mar 2, 2006
PharmaLive.com (press release), Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer ...
Lehman Brothers Ninth Annual Global Healthcare Conference to ... Mar 2, 2006
PR Newswire (press release), About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection ...
Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ... Feb 28, 2006
Cancer Consultants (press release), However, recent induction regimens have incorporated newer drugs such as Thalomid® (thalidomide), Revlimid® (lenalidomide), and Velcade® (bortezomib). ...
Bortezomib (Velcade) Shows Strong Survival Benefit in Relapsed ... Dec 13, 2005
DG News ...from the international, Assessment of Proteasome Inhibition for Extending Remissions (APEX) indicate that the clinical benefits of bortezomib monotherapy in ...
Bortezomib (Velcade) and Capecitabine (Xeloda) in Combination ... Dec 9, 2005
DG News SAN ANTONIO, TX -- December 9, 2005 -- A small phase 1 study has shown that bortezomib (Velcade) used in combination with capecitabine (Xeloda) is safe and well ...
VELCADE(R) (bortezomib) for Injection Single-Agent and Combination ... Dec 12, 2005
Yahoo! News (press release) ...one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should ...
Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) ... Dec 8, 2005
PR Newswire (press release), Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer ...
Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) ... Dec 8, 2005
PR Newswire (press release), About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection ...
Cytogen's QUADRAMET(R) Demonstrates Broad Anticancer Activity in ... Dec 12, 2005
PR Newswire (press release), ...announced today the presentation of preclinical data on its flagship product QUADRAMET(R) (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade(R ...
Cytogen's QUADRAMET(R) Demonstrates Broad Anticancer Activity in ... Dec 12, 2005
Yahoo! News (press release) ...the presentation of preclinical data on its flagship product QUADRAMET® (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade®, Millennium ...
Multiple myeloma: NPI-0052, a compound from marine bacteria ... Nov 19, 2005
Xagena.it, ..." Proteasome inhibition is a key therapeutic target and Bortezomib ( Velcade ) was the first in a new class of compounds in multiple myeloma. ...
Combination of QUADRAMET(R) and Novel First-in-class Proteasome ... Nov 28, 2005
PR Newswire (press release), ...initiation of a multicenter Phase I clinical trial to investigate the use of QUADRAMET(R) (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade(R ...
Compound from Salinispora (marine bacteria) kills blood cancer ... Nov 21, 2005
News-Medical.net, ..."Proteasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of compounds in multiple myeloma. ...
Results from Preclinical Studies of Gemin X's GX15-070 Presented ... Dec 12, 2005
CCNMatthews (press release), ...study evaluated GX15-070 in the treatment of mantle cell lymphoma (MCL), both as a monotherapy and in combination with the bortezomib (Velcade ® ) proteasome ...
Kosan Reports Interim Results of KOS-953 Clinical Trials in ... Dec 12, 2005
PR Newswire (press release), Data from a Phase I single-agent clinical trial and a Phase Ib combination trial of KOS-953 co-administered with bortezomib (Velcade(R)) demonstrated early ...
Combination of QUADRAMET(R) and Novel First-in-class Proteasome ... Nov 28, 2005
Yahoo! News (press release) ...a multicenter Phase I clinical trial to investigate the use of QUADRAMET® (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade®, Millennium ...
Human Genome Sciences Reports Results of Phase 2 Clinical Trial of ... Dec 12, 2005
Yahoo! News (press release) The preclinical data also demonstrate that HGS-ETR1 enhances the tumor-killing activity of bortezomib and doxorubicin.(2) Further study of HGS-ETR1 in ...
Survival boosted by six months with Velcade Dec 14, 2005
Cancerfacts.com, The study from the largest randomized international study of bortezomib (VELCADE®) in relapsed myeloma were presented this week by Dr. Paul Richardson of the ...
Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination ... Dec 8, 2005
PR Newswire (press release), ...breast cancer reported on today, KOS-953 is also being evaluated in a Phase I single-agent and Phase Ib combination clinical trial with bortezomib (Velcade(R ...
TopoTarget and CuraGen's PXD101 Reveals Promising Side Effect ... Dec 13, 2005
PharmaLive.com (press release), Moreover, the combination of PXD101 with Velcade® (bortezomib) showed greater growth-inhibitory activity, as compared to either drug used alone, on a MM cell ...
Millennium: Velcade set for cancer consolidation Dec 13, 2005
Pharmaceutical Business Review ...based on median follow-up of 22 months, demonstrated a median overall survival of 30 months in patients treated with Velcade (bortezomib), compared with 24 ...
(PRN) - Brookstone to Broadcast Conference Call Via Live Webcast ... Dec 12, 2005
Bolsamania.com, Web ... [+. PRN) - VELCADE(R) (bortezomib) for Injection Continues to Show Impressive Results in a Variety of Lymphomas ... [+. ...
Highlights of rising and falling US stocks Dec 12, 2005
Investor's Business Daily (subscription) Cytogen Corp. (CYTO) said preclinical data for its Quadramet oncology product used in combination with bortezomib demonstrated broad anticancer activity in a ...
(PRN) - PennFuture Praises House for Sending Dirty Air Bill Back ... Dec 12, 2005
Bolsamania.com, ...(PRN) - VELCADE(R) (bortezomib) for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients ... [+. ...
(PRN) - ATCT Announce the Addition of Michael Nurse to the Board ... Dec 8, 2005
Bolsamania.com, ...(PRN) - Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) for Injection From the 47th Annual Meeting of the American Society of Hematology ... ...
(PRN) - Mercury and Digital China Expand Strategic Alliance to ... Dec 6, 2005
Bolsamania.com, ...[+]. (PRN) - New Data on VELCADE(R) (bortezomib) for Injection to Be Presented at Upcoming American Society of Hematology Meeting ... [+. ...
CuraGen and TopoTarget Announce Presentation of PXD101 Phase I ... Dec 12, 2005
PharmaLive.com (press release), Moreover, the combination of PXD101 with Velcade(R) (bortezomib) showed greater growth-inhibitory activity, as compared to either drug used alone, on a ...
Bruce A. Leicher Joins Antigenics As General Counsel Dec 13, 2005
Yahoo! News (press release) While at Millennium, he was a leader in the creation of the commercial infrastructure to launch Velcade® (bortezomib) -- the first proteasome inhibitor ...
Human Genome Sciences Reports Results of Phase 1 Clinical Trials ... Nov 17, 2005
PR Newswire (press release), ...agonistic monoclonal antibodies to the TRAIL receptors R1 and R2 induce cell death and potentiate the effect of chemotherapy and bortezomib in primary and ...
|
|
